¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¼º¸ðº´¿ø 2019³â Á¦28ȸ ´ëÇÑÀü¸³¼±ÇÐȸ Á¤±âÇмú´ëȸ : 2019-03-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
​¼­¿ï¼º¸ðº´¿ø 2019³â Á¦28ȸ ´ëÇÑÀü¸³¼±ÇÐȸ Á¤±âÇмú´ëȸ : 2019-03-09
±³À°ÀÏÀÚ : 2019-03-09
±³À°Àå¼Ò : ¼­¿ï¼º¸ðº´¿ø ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : 2019³â Á¦28ȸ ´ëÇÑÀü¸³¼±ÇÐȸ Á¤±âÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±â°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀü¸³¼±ÇÐȸ  
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 031-987-5963  
À̸ÞÀÏ : gaonpco@gaonpco.com      
±³À°Á¾·ù : ºñ´¢±â°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 09:00~09:50 Podium Session  Á¶¹®±â(¿øÀڷº´¿ø) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 09:50~10:05 Update in Active Surveillance  ±èº´ÈÆ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 10:05~10:20 Role of Prebiopsy MRI  ÀüȲ±Õ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 10:20~10:35 Clinical Utility of Prostate Health Index (phi) in Korea  ±èÁ¤Çö(°­¿øÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 10:35~10:50 Initial Experience of Focal High-Intensity Focused Ultrasound  ÀÌÇйÎ(¼­¿ïÀÇ´ë) 
È޽Ġ03-09 ¸¶¸®¾ÆȦ 10:50~11:10 Coffee Break  () 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 11:10~11:30 Á¤³âÅðÀÓ ±â³äƯ°­  ±èõÀÏ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 11:30~12:00 Biomarkers in Prostate Cancer Management  Yves Fradet(Laval University Quebec Canada) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 12:00~12:15 Microbiota in Patients with CP/CPPS  Á¤½ÂÀÏ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 12:15~12:30 Is CP/CPPS an Infectious Disease of the Prostate?  Á¶ÀÎâ(±¹¸³°æÂûº´¿ø) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 12:30~12:50 Why Should We Consider BTAs (Bone Targeted Agents) for mCRPC?  Á¤À翵(±¹¸³¾Ï¼¾ÅÍ) 
½Ä»ç 03-09 ¸¶¸®¾ÆȦ 12:50~13:40 lunch  () 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 13:40~14:10 Treatment of Advanced Prostate Cancer: A Changing Algorithm  Yves Fradet(Laval University Quebec Canada) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 14:10~14:25 Aquablation Therapy for BPH  ½ÅÀ¯¼·(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 14:25~14:40 Current Update of BPH Surgery  Á¶Á¤±â(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 14:40~14:55 Male Incontinence: The Etiology or Basis of Treatment  ±èÀçÇå(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 14:55~15:10 Male Underactive Bladder: Diagnosis and Surgical Treatment Options  Á¶¼ºÅÂ(ÇѸ²ÀÇ´ë) 
È޽Ġ03-09 ¸¶¸®¾ÆȦ 15:10~15:30 Coffee Break  () 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 15:30~16:20 Podium Session 2  ¹ÚÈ«¼®(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 16:20~16:35 Evolving Treatment Paradigm of mCSPC  ¹ÚÁ¾¿í(¿øÀڷº´¿ø) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 16:35~16:50 New Directions in Non-metastatic CRPC: Key Facet for Optimal Management  ±è¼öµ¿(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 16:50~17:05 Is There Optimal Treatment Sequence for mCRPC?  ÇÏÀ¯½Å(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-09 ¸¶¸®¾ÆȦ 17:05~17:20 Does Immune Checkpoint Inhibitor Works in Prostate Cancer?  ±è¼ºÇÑ(±¹¸³¾Ï¼¾ÅÍ) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¼º¸ðº´¿ø 2019³â Á¦28ȸ ´ëÇÑÀü¸³¼±ÇÐȸ Á¤±âÇмú´ëȸ : 2019-03-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¿ø±¤´ëÇб³º´¿ø Á¦7ȸ ¿ø±¤´ëÇб³ ³»°ú ¿¬¼ö°­Á : 2019-03-09
´ÙÀ½±Û °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø 11th Catholic Vascular Ultrasound Symposium & workshop 2019 : 2019-03-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 15 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 10 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 14 2024-05-28
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 12 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 31 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 121 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 41 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 120 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 34 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 23 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 19 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 43 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 13 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 21 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 12 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷